See more : Bloomios, Inc. (BLMS) Income Statement Analysis – Financial Results
Complete financial analysis of Ginkgo Bioworks Holdings, Inc. (DNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ginkgo Bioworks Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Red Eagle Mining Corporation (RDEMF) Income Statement Analysis – Financial Results
- Vanstar Mining Resources Inc. (VSR.V) Income Statement Analysis – Financial Results
- VizConnect, Inc. (VIZC) Income Statement Analysis – Financial Results
- JLK, Inc. (322510.KQ) Income Statement Analysis – Financial Results
- Zhejiang Zhongxin Fluoride Materials Co.,Ltd (002915.SZ) Income Statement Analysis – Financial Results
Ginkgo Bioworks Holdings, Inc. (DNA)
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2001 |
|---|---|---|---|---|---|---|
| Revenue | 251.46M | 477.71M | 313.84M | 76.66M | 54.18M | 98.29M |
| Cost of Revenue | 54.01M | 204.22M | 129.69M | 15.61M | 0.00 | 0.00 |
| Gross Profit | 197.45M | 273.49M | 184.15M | 61.05M | 54.18M | 98.29M |
| Gross Profit Ratio | 78.52% | 57.25% | 58.68% | 79.64% | 100.00% | 100.00% |
| Research & Development | 580.62M | 1.05B | 1.15B | 159.77M | 96.30M | 100.48M |
| General & Administrative | 385.03M | 1.43B | 862.95M | 38.31M | 29.48M | 77.39M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 385.03M | 1.43B | 862.95M | 38.31M | 29.48M | 77.39M |
| Other Expenses | 96.21M | 7.63M | -1.73M | 16.13M | 1.57M | 0.00 |
| Operating Expenses | 1.06B | 2.48B | 2.01B | 198.07M | 125.78M | 177.87M |
| Cost & Expenses | 1.12B | 2.69B | 2.14B | 213.68M | 125.78M | 177.87M |
| Interest Income | 57.22M | 20.26M | 837.00K | 2.58M | 5.76M | 0.00 |
| Interest Expense | 93.00K | 106.00K | 2.37M | 2.39M | 2.42M | 0.00 |
| Depreciation & Amortization | 71.55M | 61.63M | 29.08M | 13.86M | 10.76M | 14.80M |
| EBITDA | -821.29M | -2.06B | -1.81B | -108.59M | -106.66M | -219.71M |
| EBITDA Ratio | -326.62% | -456.43% | -598.26% | -140.25% | -149.58% | -223.55% |
| Operating Income | -864.41M | -2.21B | -1.83B | -137.03M | -71.60M | -234.51M |
| Operating Income Ratio | -343.76% | -462.41% | -582.62% | -178.75% | -132.14% | -238.60% |
| Total Other Income/Expenses | -28.53M | 87.55M | -9.66M | 12.19M | -48.24M | 0.00 |
| Income Before Tax | -892.94M | -2.12B | -1.84B | -124.83M | -119.84M | 0.00 |
| Income Before Tax Ratio | -355.11% | -444.08% | -585.69% | -162.85% | -221.16% | 0.00% |
| Income Tax Expense | -71.00K | -15.03M | -1.48M | 1.89M | 22.00K | 0.00 |
| Net Income | -892.87M | -2.10B | -1.83B | -126.61M | -119.33M | 0.00 |
| Net Income Ratio | -355.08% | -440.63% | -583.12% | -165.16% | -220.23% | 0.00% |
| EPS | -18.37 | -50.15 | -53.83 | -0.09 | -0.08 | 0.00 |
| EPS Diluted | -18.37 | -50.12 | -53.81 | -0.09 | -0.08 | 0.00 |
| Weighted Avg Shares Out | 48.61M | 41.98M | 34.00M | 1.49B | 1.49B | 0.00 |
| Weighted Avg Shares Out (Dil) | 48.61M | 42.00M | 34.01M | 1.49B | 1.49B | 0.00 |
Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better
Ginkgo Bioworks reported solid Q3 results, but underlying performance was weaker than the financials suggest after accounting for meaningless non-cash revenue. Ginkgo's new business model focuses on upfront value creation and solutions which reduce friction in the customer acquisition process....
Ginkgo Bioworks: Not Enough Progress
Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues. Despite cost cutting efforts, Ginkgo continues to report large losses, and $325 million of cash was burned in the first nine months...
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q3 2024 Results Conference Call November 12, 2024 5:30 PM ET Company Participants Megan LeDuc - Manager, IR Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Conference Call Participants Tejas Savant...
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $2.40. This compares to loss of $3.60 per share a year ago.
What's happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA testing company
DNA-testing company 23andMe (Nasdaq: ME), once an industry leader that attracted millions of customers, including rapper Snoop Dogg and investor Warren Buffett, has announced significant cuts to its operations, with plans to lay off 200 employees, or roughly 40% of...
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results
Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck BOSTON , Nov....
Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing
BOSTON , Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of a previously announced partnership with Merck , known as...
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small...
Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation
Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON , Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that...
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63 in the latest trading session, marking a -1.55% move from the prior day.
Source: https://incomestatements.info
Category: Stock Reports